Titlebook: Management of Acute Coronary Syndromes; Christopher P. Cannon Book 1999 Springer Science+Business Media New York 1999 myocardial infarctio

FEMUR

Management of Acute Coronary Syndromes978-1-59259-731-4Series ISSN 2196-8969 Series E-ISSN 2196-8977

BUST

Early Identification and Treatment of Patients with Acute Coronary Syndromesequates 1 hour of delay in reperfusion to an increase in absolute mortality by approximately 1%, or 10 lives per thousand; this is a linear relationship in the first 4–6 h following symptom onset . (Fig. 1). Therefore, it is imperative that time be considered as much of an adjunct to the treatment o

Decrepit

Thrombolytic Therapy for Acute Myocardial Infarction With ST-Segment Elevationed to have contributed approximately one-third each to this decline .. Progress has resulted from improved understanding of AMI pathophysiology (a result of extensive basic and clinical research efforts), as well as pathophysiology-based therapies, of which the primary goal in ST-segment elevation M

指耕作

脊椎動(dòng)物

β-Adrenergic Blockers, Calcium Channel Blockers, and Nitrates and MI associated with ST-segment depression), to a ruptured plaque with extensive thrombus and complete occlusion of the artery (MI associated with ST-segment elevation). In the mid-to-late 1990s, however, it has been appreciated that this two-component pathophysiologic model of the acute coronary

expository

Angiotensin-Converting Enzyme Inhibitors in Acute Coronary Syndromesptide angiotensin I. Angiotensin I, in turn, is cleaved into the octapeptide angiotensin II by angiotensin-converting enzyme (ACE), a ubiquitous enzyme present on the surface of endothelial cells. The many important effects of the renin-angiotensin system discussed in this chapter may be attributed

Veneer

L. Kristin Newby MD,W. Brian Gibler MD,Robert H. Christenson PhD,E. Magnus Ohman MD

正式通知

散開(kāi)

硬化